Dr. Nehad Alajez is currently appointed as Principal Investigator at the Translational Cancer and Immunity Center (TCIC), Qatar Biomedical Research Institute (QBRI) and joint Professor at the College of Health & Life Sciences, Hamad Bin Khalifa University (HBKU). Dr. Alajez earned his PhD in tumor immunology from the University of Pittsburgh School of Medicine in USA and subsequently completed his postdoctoral training at the Princess Margaret Cancer Center (University Health Network), a premier research institute in Toronto, Canada. His main research interests were to investigate the role of the Polycomb gene family and non-coding microRNAs in driving cancer progression and their potential utilization for targeted therapies. Dr. Alajez is a recipient of several prestigious awards and have published more than 100 articles in top-tier ISI-indexed journals including Blood, Cancer Research, Cell Death and Differentiation, Cell Death and Disease, Signal Transduction and Targeted Therapy, Molecular Therapy (family journals), EMBO Molecular Medicine, and in Science Translational Medicine, with approximately 5,000 citation and an h-index of 37 and i10-index of 78. Prior to his current appointment, Dr. Alajez was appointed as an Associate Professor (2015-2018) at King Saud University College of Medicine, Kingdom of Saudi Arabia. Dr. Alajez main research interest focuses on “translational oncology research” with main emphasis on novel biomarker discovery and targeted therapeutics for breast cancers. In particular, Dr. Alajez team is studying non-coding RNAs (microRNA and lncRNA) as disease and predictive biomarkers for patients’ response to therapy. Dr. Alajez has strong expertise in transcriptome analysis, non-coding RNAs, and biomarker discovery field. Dr. Alajez is ranked among the top 2% most cited scientist globally currently on the editorial board of several journals. Dr. Alajez have received several major grants, including funding from Qatar National Research Fund.
